Sign inJoin waitlistJoin the waitlist

Yesid Alvarado

Associate Professor · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
University of Texas Health Science Center at San Antonio
2009–2011
Internal Medicine
Texas Tech University Health Sciences Center at Lubbock
2003–2006
University of Texas M D Anderson Cancer Center
2001–2003
Doctor of Medicine
1990–1994

Research

Ibrutinib and Venetoclax for First-Line Treatment of CLL
New England Journal of Medicine · 2019 · 426 citations
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
Journal of Clinical Oncology · 2021 · 294 citations
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
The Lancet Haematology · 2020 · 280 citations

Hagop Kantarjian
110 papers
Elias Jabbour
95 papers
Tapan Kadia
94 papers
Guillermo Garcia-Manero
92 papers
GB
Gautam Borthakur
84 papers
Courtney DiNardo
80 papers
Naval Daver
79 papers
Naveen Pemmaraju
68 papers
Nicholas Short
68 papers · 3 as a fellow
KS
Koji Sasaki
52 papers · 2 as a fellow
Nitin Jain
51 papers
Marina Konopleva
50 papers

Clinical trials

Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML
Principal investigator · Withdrawn · Phase 1, Phase 2
M.D. Anderson Cancer Center
2020
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2018–2026
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Principal investigator · Completed · Phase 1, Phase 2
M.D. Anderson Cancer Center
2013–2023